Paratek expands commercial portfolio with Optinose

Paratek has agreed to pay $1 per share if Xhance achieves $150m in net sales in any calendar year before 31 December 2028. Credit: MacroEcon/Shutterstock. Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings. The companies signed a definitive merger agreement in March 2025. The portfolio of Paratek now includes its lead antibiotic, Nuzyra (omadacycline), and Optinose’s Xhance (fluticasone propionate). The acquisition encompasses all outstanding shares of Optinose, including debt assumption and full payment of contingent value rights (CVRs). Optinose shareholders approved the merger on 16 May. The transaction was supported by capital from Paratek, Novo Holdings and B-FLEXION Life Sciences, and debt financing from Oaktree Capital Management funds. The shareholders received $9 per share in cash and CVRs for up to $5 per share, contingent upon Xhance reaching certain net revenue milestones. GlobalData Strategic Intelligence Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Paratek has agreed to pay $1 per share on Xhance’s achievement of $150m in net sales in any calendar year before 31 December 2028, and an additional $4 per share if they reach $225m before 31 December 2029. Nuzyra is designed to combat tetracycline resistance and functions against a broad range of bacteria, including drug-resistant strains. It is available in both oral and intravenous formulations for treating community-acquired bacterial pneumonia and acute bacterial skin infections. Xhance, a drug-device combination product, utilises the exhalation delivery system, which delivers the topical steroid to the deep nasal cavity areas. Paratek Pharmaceuticals CEO Evan Loh stated: “Adding Xhance to our portfolio is a pivotal first step in achieving our long-term vision to become a multi-product speciality therapeutics company, focused on addressing significant unmet medical needs. “This transaction establishes a strong platform for us to continue to leverage these capabilities as we move forward to explore opportunities to expand our portfolio through future product acquisitions.” Lazard and Skadden, Arps, Slate and Meagher & Flom provided exclusive financial and legal advisory services to Paratek. Evercore and Hogan Lovells US provided exclusive financial and legal advisory services to Optinose. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now